Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATAI NASDAQ:CMPS NASDAQ:MNMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATAIatai Life Sciences$5.38+2.8%$4.52$1.03▼$5.97$1.25B1.584.02 million shs2.56 million shsCMPSCOMPASS Pathways$6.38-0.9%$4.82$2.25▼$6.63$611.62M2.211.80 million shs1.34 million shsMNMDMind Medicine (MindMed)$12.39-1.4%$9.83$4.70▼$12.76$938.95M2.551.50 million shs790,892 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATAIatai Life Sciences0.00%-0.76%+14.44%+90.18%+350.86%CMPSCOMPASS Pathways0.00%+10.86%+25.10%+94.26%+3.54%MNMDMind Medicine (MindMed)0.00%+17.71%+36.23%+74.44%+125.49%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATAIatai Life Sciences$5.38+2.8%$4.52$1.03▼$5.97$1.25B1.584.02 million shs2.56 million shsCMPSCOMPASS Pathways$6.38-0.9%$4.82$2.25▼$6.63$611.62M2.211.80 million shs1.34 million shsMNMDMind Medicine (MindMed)$12.39-1.4%$9.83$4.70▼$12.76$938.95M2.551.50 million shs790,892 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATAIatai Life Sciences0.00%-0.76%+14.44%+90.18%+350.86%CMPSCOMPASS Pathways0.00%+10.86%+25.10%+94.26%+3.54%MNMDMind Medicine (MindMed)0.00%+17.71%+36.23%+74.44%+125.49%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATAIatai Life Sciences 2.86Moderate Buy$11.25109.30% UpsideCMPSCOMPASS Pathways 2.63Moderate Buy$16.29155.46% UpsideMNMDMind Medicine (MindMed) 3.00Buy$26.50113.92% UpsideCurrent Analyst Ratings BreakdownLatest ATAI, MNMD, and CMPS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/27/2025ATAIatai Life SciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025CMPSCOMPASS PathwaysWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025MNMDMind Medicine (MindMed)Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/23/2025ATAIatai Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$15.008/20/2025ATAIatai Life SciencesZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/4/2025CMPSCOMPASS PathwaysHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$45.00 ➝ $40.008/4/2025MNMDMind Medicine (MindMed)OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$25.008/1/2025CMPSCOMPASS PathwaysCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$15.008/1/2025MNMDMind Medicine (MindMed)Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.007/30/2025ATAIatai Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.00 ➝ $15.007/29/2025ATAIatai Life SciencesOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$14.00(Data available from 10/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATAIatai Life Sciences$2.31M544.20N/AN/A$0.69 per share7.79CMPSCOMPASS PathwaysN/AN/AN/AN/A$2.26 per shareN/AMNMDMind Medicine (MindMed)N/AN/AN/AN/A$3.21 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATAIatai Life Sciences-$149.27M-$0.69N/AN/AN/AN/A-85.43%-64.38%11/12/2025 (Estimated)CMPSCOMPASS Pathways-$155.12M-$1.84N/AN/AN/AN/A-87.89%-57.77%10/30/2025 (Estimated)MNMDMind Medicine (MindMed)-$108.68M-$1.53N/AN/AN/AN/A-50.24%-39.41%11/6/2025 (Estimated)Latest ATAI, MNMD, and CMPS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails10/30/2025Q3 2025CMPSCOMPASS Pathways-$0.40N/AN/AN/AN/AN/A8/14/2025Q2 2025ATAIatai Life Sciences-$0.12-$0.14-$0.02-$0.14N/A$0.72 million7/31/2025Q2 2025CMPSCOMPASS Pathways-$0.37-$0.38-$0.01-$0.41N/AN/A7/31/2025Q2 2025MNMDMind Medicine (MindMed)-$0.38-$0.50-$0.12-$0.50N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATAIatai Life SciencesN/AN/AN/AN/AN/ACMPSCOMPASS PathwaysN/AN/AN/AN/AN/AMNMDMind Medicine (MindMed)N/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATAIatai Life Sciences0.024.024.02CMPSCOMPASS Pathways0.168.828.82MNMDMind Medicine (MindMed)0.224.984.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATAIatai Life Sciences28.41%CMPSCOMPASS Pathways46.19%MNMDMind Medicine (MindMed)27.91%Insider OwnershipCompanyInsider OwnershipATAIatai Life Sciences26.80%CMPSCOMPASS Pathways3.93%MNMDMind Medicine (MindMed)2.26%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATAIatai Life Sciences80233.78 million171.13 millionOptionableCMPSCOMPASS Pathways12095.94 million92.17 millionOptionableMNMDMind Medicine (MindMed)4076.09 million74.37 millionOptionableATAI, MNMD, and CMPS HeadlinesRecent News About These CompaniesMind Medicine (MindMed) (NASDAQ:MNMD) Reaches New 12-Month High - What's Next?4 hours ago | marketbeat.comMind Medicine (MindMed) (NASDAQ:MNMD) Stock Price Down 6.8% - Should You Sell?September 30, 2025 | marketbeat.comMind Medicine (MindMed) Inc.'s (NASDAQ:MNMD) high institutional ownership speaks for itself as stock continues to impress, up 26% over last weekSeptember 30, 2025 | finance.yahoo.comMind Medicine (MindMed) (NASDAQ:MNMD) Hits New 12-Month High - Should You Buy?September 29, 2025 | marketbeat.comDaniel Karlin Sells 7,704 Shares of Mind Medicine (MindMed) (NASDAQ:MNMD) StockSeptember 27, 2025 | insidertrades.comMind Medicine (MindMed) (NASDAQ:MNMD) Insider Sells $75,268.08 in StockSeptember 26, 2025 | marketbeat.comMind Medicine (MindMed) (NASDAQ:MNMD) Insider Sells $110,186.06 in StockSeptember 26, 2025 | marketbeat.comMind Medicine (MindMed) (NASDAQ:MNMD) CEO Sells $252,036.69 in StockSeptember 26, 2025 | marketbeat.comMind Medicine (MindMed) (NASDAQ:MNMD) Stock Price Up 7% - Should You Buy?September 23, 2025 | marketbeat.comMindMed Announces New Employee Inducement GrantsSeptember 22, 2025 | businesswire.comGoldman Sachs Group Inc. Has $1.12 Million Position in Mind Medicine (MindMed) Inc. $MNMDSeptember 22, 2025 | marketbeat.comNew MindMed Retrospective Study Presented at Psych Congress 2025 Reveals High Rates of Suicidal Ideation (SI) in Adults with Generalized Anxiety Disorder (GAD)September 19, 2025 | financialpost.comFNew MindMed Retrospective Study Presented at Psych Congress 2025 Reveals High Rates of Suicidal Ideation (SI) in Adults with Generalized Anxiety Disorder (GAD)September 19, 2025 | businesswire.comMind Medicine (MindMed) Inc. (NASDAQ:MNMD) Receives Average Recommendation of "Buy" from BrokeragesSeptember 17, 2025 | marketbeat.comMindMed Announces New Employee Inducement GrantsSeptember 8, 2025 | businesswire.comJournal of the American Medical Association (JAMA) Publishes Results from First-Ever Randomized, Placebo-Controlled Clinical Trial Assessing the Dose-Dependent Efficacy of ...September 4, 2025 | finance.yahoo.comJournal of the American Medical Association (JAMA) Publishes Results from First-Ever Randomized, Placebo-Controlled Clinical Trial Assessing the Dose-Dependent Efficacy of MM120 (Lysergide D-Tartrate, LSD) in Generalized Anxiety Disorder (GAD)September 4, 2025 | businesswire.comMind Medicine (MindMed) Inc. (MNMD)’s MM120 Earns FDA Breakthrough Status in Anxiety TreatmentSeptember 2, 2025 | finance.yahoo.comMindMed to Participate in September Investor ConferencesAugust 28, 2025 | financialpost.comFMindMed Reports Strong Phase 3 Trial Progress and Leadership AppointmentAugust 25, 2025 | theglobeandmail.comIf You'd Invested $1,000 in Mind Medicine (MNMD) Stock 5 Years Ago, Here's How Much You'd Have TodayAugust 12, 2025 | fool.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeATAI, MNMD, and CMPS Company Descriptionsatai Life Sciences NASDAQ:ATAI$5.38 +0.15 (+2.77%) As of 02:39 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.COMPASS Pathways NASDAQ:CMPS$6.38 -0.06 (-0.86%) As of 02:38 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.Mind Medicine (MindMed) NASDAQ:MNMD$12.39 -0.17 (-1.37%) As of 02:39 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Behind D-Wave's Massive Week (And Why Rivals Also Popped) Cheap Chipotle? Why CMG Stock Could Be Ready for a Comeback Alphabet: After Its Best Quarter in Decades, Is It Time to Buy? Best Stocks Under $15? 3 Low-Priced Picks With Upside After Trump Deal, Can Meta Stock Withstand TikTok’s Onslaught? Starbucks Stock Slumps; This Competitor Shows Strength Broadcom’s VMware Push Takes Aim at Microsoft, Google, & Amazon How Berkshire's OxyChem Buy Cements Its Long-Term Strength Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
